In addition, another in vivo study has shown that treatment with the anthocyanin cyanidin-3-glucoside (6 mg/mL twice a week for 25 days), in a xenograft model bearing BT-474 BC cells (expressing HER2), was able to potentiate the antineoplastic effects of trastuzumab [132]. This evidence concerns the gene ERBB2 and breast cancer.